dr. M.S. (Marjolein) de Bruin-Weller

dr. M.S. (Marjolein) de Bruin-Weller

Full Professor
dr. M.S. (Marjolein) de Bruin-Weller
  • Dermatology and Allergology

Research Programs

Infection & Immunity



Marjolein de Bruin-Weller  is a dermatologist and full professor in atopic dermatitis and head of the National Expertise Center of Atopic Dermatitis,  situated  in the dpt. of Dermatology and Allergology of the University Medical Center of Utrecht, The Netherlands


After her training in physiotherapy (1979-1983), she started her medical training at the University of Leiden and graduated in 1990. After this she started as a PhD candidate at Astmacenter Heideheuvel, Hilversum, the Netherlands, supervised by Professor Jan de Monchy (allergologist  University Medical Center Groningen, Professor Henk Jansen (pulmonologist University Medical Center Amsterdam) and dr. Frank Weller (pulmonologist University Medical Center Amsterdam).  In 1997 she defended her PhD thesis “Dynamics of the allergic reaction in the airways and the skin”  at the University of Groningen.


She started her training in dermatology in 1997 at the department of Dermatology/Allergology of the University Medical Center Utrecht and became a staff member at this department in 2001, with a special focus on atopic dermatitis.  In October 2018 she was appointed as Associate Professor and in December 2021 as full professor in atopic dermatitis.

Her major interest is clinical and translational research in atopic dermatitis. She is principle investigator in several clinical trials and investigator-initiated studies focused on difficult to treat atopic dermatitis and systemic immunosuppressive and immuno-modulating treatment. For translational, she closely collaborates with the Center of Translational Immunology in Utrecht (Professor Femke van Wijk).

Together with Femke van Wijk, Marjolein de Bruin leads the Utrecht Atopic Dermatitis Research Group.


In 2018 she imitated  the BioDay Registry in the Netherlands together with dr. Marie-Louise Schuttelaar from the department of Dermatology of the University Medical Center of Groningen. This register is focused on new systemic treatments in atopic dermatitis and includes a lot of data concerning atopic dermatitis (signs, symptoms, quality of life, work impairment) as well as data concerning atopic co-morbidities. At the end of 2021, 14 centers in the Netherlands are participating in the BioDay Registry and   >1000 patients are included.


Marjolein de Bruin-Weller  is a member of the Expertise group Allergy and Eczema Dutch Society of Dermatology and Venereology),  the  European Task Force of Atopic Dermatitis  (ETFAD) , the International Eczema Council (IEC)  and the  GA²LEN ADCARE Task Force.  She is chair of the advisory board Dutch Patient Society for Atopic Dermatitis (VMCE).




Side Activities

External activities (non paid)

Chair Advisory board Dutch patient society for atopic dermatitis (VMCE)

ExComm Member GA²LEN

Member Steering committee of the ADCARE Task Force

Member Dutch Society of Dermatology and Venereology (NVDV)

Member European Academy of Dermatology and Venereology (EADV)

Member European Task Force of Atopic Dermatitis (ETFAD)

Member International Eczema Council (IEC)

Member Horizonscan inflammatory diseases (Zorginstituut Nederland)

Member “ geneesmiddelencommissie FMS”

Chair working group “dure geneesmiddelen” NVDV


Collaboration pharmaceutical industry (paid)

International advisory board member:

AbbVie, Almirall, Arena, Aslan, Eli Lilly, Galderma, Janssen, Leo Pharma, Pfizer, Regeneron, Sanofi-Genzyme

National advisory board member:

AbbVie, Eli Lilly, Galderma, Leo Pharma, Pfizer, and Sanofi-Genzyme


AbbVie, Almirall, Leo Pharma, Eli Lilly, Galderma, Pfizer, Regeneron, and Sanofi- Genzyme


AbbVie, Almirall, Eli Lilly, Galderma, LeoPharma, Pfizer, Regeneron, and Sanofi- Genzyme

 Investigator Initiated Studies:

AbbVie, Leo Pharma, Eli-Lilly, Regeneron and Sanofi-Genzyme

Research Output (161)

Dupilumab in daily practice for the treatment of pediatric atopic dermatitis:28-week clinical and biomarker results from the BioDay registry

Kamphuis Esmé, Boesjes Celeste M., Loman Laura, Bakker Daphne S., Poelhekken Mila, Zuithoff Nicolaas P.A., Kamsteeg Marijke, Romeijn Geertruida L.E., van Wijk Femke, de Bruin-Weller Marjolein S., de Graaf Marlies, Schuttelaar Marie L.A. 5 Dec 2022, In: Pediatric Allergy and Immunology. 33

Daily Practice Experience of Baricitinib Treatment for Patients with Difficult-to-Treat Atopic Dermatitis:Results from the BioDay Registry

Boesjes Celeste M., Kamphuis Esmé, Zuithoff Nicolaas P.A., Bakker Daphne S., Loman Laura, Spekhorst Lotte S., Haeck Inge, Kamsteeg Marijke, VAN LYNDEN-VAN NES Anneke M.T., Garritsen Floor M., Politiek Klaziena, Oldhoff Marja, DE GRAAF Marlies, Schuttelaar Marie L.A., DE BRUIN-WELLER Marjolein S. 24 Nov 2022, In: Acta Dermato-Venereologica. 102

Association of Serum Dupilumab Levels at 16 Weeks with Treatment Response and Adverse Effects in Patients with Atopic Dermatitis:A Prospective Clinical Cohort Study from the BioDay Registry

Spekhorst Lotte S., De Graaf Marlies, Loeff Floris, Zuithoff Nicolaas P.A., Bakker Daphne, Boesjes Celeste M., Thijs Judith, Achten Roselie, Van Wijk Femke, Rispens Theo, De Bruin-Weller Marjolein S. 2 Nov 2022, In: JAMA Dermatology. 158 , p. 1409-1413 5 p.

Dupilumab Drug Survival and Associated Predictors in Patients With Moderate to Severe Atopic Dermatitis:Long-term Results From the Daily Practice BioDay Registry

Spekhorst Lotte S, de Graaf Marlies, Zuithoff Nicolaas P A, van den Reek Juul M P A, Kamsteeg Marijke, Boesjes Celeste M, Romeijn Geertruida L E, Loman Laura, Haeck Inge, Oosting Albert J, de Boer-Brand Astrid, Touwslager Wouter R H, Flinterman Annebeth, van Lynden-van Nes Anneke M T, Gostynski Antoni H, de Bruin-Weller Marjolein S, Schuttelaar Marie-Louise 10 Aug 2022, In: JAMA Dermatology. 158 , p. 1048-1056 9 p.

Eczema control and treatment satisfaction in atopic dermatitis patients treated with dupilumab - a cross-sectional study from the BioDay registry

Oosterhaven Jart A F, Spekhorst Lotte S, Zhang Junfen, Voorberg Angelique N, Romeijn Geertruida L E, Boesjes Celeste M, de Graaf Marlies, de Bruin-Weller Marjolein S, Schuttelaar Marie L A Jun 2022, In: The journal of dermatological treatment. 33 , p. 1986-1989 4 p.

Ocular surface disease is common in moderate-to-severe atopic dermatitis patients

Achten Roselie E, Bakker Daphne S, van Luijk Chantal M, van der Wal M Marlot, de Graaf Marlies, van Wijk Femke, Zuithoff Nicolaas P A, van der Rijst Lisa P, Boesjes Celeste M, Thijs Judith L, de Boer Joke H, de Bruin-Weller Marjolein S 16 Mar 2022, In: Clinical and Experimental Allergy. 52 , p. 801-805 5 p.

Identification of Risk Factors for Dupilumab-associated Ocular Surface Disease in Patients with Atopic Dermatitis

Achten Roselie E, Van Luijk Chantal, Van der Rijst Lisa, Bakker Daphne, Spekhorst Lotte, Zuithoff Nicolaas, Schuttelaar Marie, Romeijn Geertruida, Voorberg Angelique, Kamsteeg Marijke, Haeck Inge, De Graaf Marlies, Thijs Judith, De Boer Joke, De Bruin-Weller Marjolein 31 Jan 2022, In: Acta Dermato-Venereologica. 102 , p. 1-7

Patient-centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis

Spekhorst Lotte S, Bakker Daphne, Drylewicz Julia, Rispens Theo, Loeff Floris, Boesjes Celeste M, Thijs Judith, Romeijn Geertruida L E, Loman Laura, Schuttelaar Marie-Louise, van Wijk Femke, de Graaf Marlies, de Bruin-Weller Marjolein S 2022, In: Allergy. 77 , p. 3398-3407 10 p.

Risk factors for conjunctivitis in atopic dermatitis patients treated with dupilumab: results from the bioday registry

Achten R., Van der Rijst L., Bakker D., Spekhorst L., Boesjes C., Zuithoff N., Knol E., Van Luijk C., De Boer J., Thijs J., De Graaf M., De Bruin-Weller M. Nov 2021, In: Allergy. 76 , p. 11-11

Unraveling heterogeneity in pediatric atopic dermatitis::identification of serum biomarker based patient clusters

Bakker D., de Graaf M., Nierkens S., Delemarre E., Knol E., van Wijk F., de Bruin-Weller M., Drylewicz J., Thijs J. Oct 2021, In: Journal of Investigative Dermatology. 141 , p. S189-S189

All research output

Thank you for your review!

Has this information helped you?

Please tell us why, so that we can improve our website.

Working at UMC Utrecht





Practical maakt gebruik van cookies

Deze website maakt gebruik van cookies Deze website toont video’s van o.a. YouTube. Dergelijke partijen plaatsen cookies (third party cookies). Als u deze cookies niet wilt kunt u dat hier aangeven. Wij plaatsen zelf ook cookies om onze site te verbeteren.

Lees meer over het cookiebeleid

Akkoord Nee, liever niet